Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study

United European Gastroenterology Journal

Volumn 3, Issue 1, 2015, Pages 72-79

  Lasson, Anders ^a   Ohman, Lena ^b,c   Stotzer, Per Ove ^b   Isaksson, Stefan ^b,c   Uberbacher, Otto ^d   Ung, Kjell Arne ^e   Strid, Hans ^b  

^a Section of Hematology   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Halland Hospital   (Sweden)

^e SKARABORG HOSPITAL   (Sweden)

Author keywords

5 Aminosalicylate; Biomarker; Calprotectin; Fecal calprotectin; Randomized controlled study; Relapse rate; Ulcerative colitis

Indexed keywords

CALGRANULIN; MESALAZINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

EID: 85006184882     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614560785     Document Type: Article

References (33)

1. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. J Crohns Colitis 2012; 6: 991-1030.
2. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-2485.
3. Schroeder KW, Tremaine WJ and Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: A randomized study. New Engl J Med 1987; 317: 1625-1629.
4. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002; 97: 1398-1407.
5. Feagan BG and Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2012; 10. www.thecochranelibrary.com.
6. Kruis W, Schreiber S, Theuer D, et al. Low dose balsa-lazide (1.5 g twice daily) and mesalazine (0.5 g, three times daily) maintained remission of ulcerative colitis, but high-dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 783-789.
7. Fockens P, Mulder CJJ, Tytgat GNJ, et al. Comparison of the efficacy and safety of 1.5 g compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Europ J Gastroenterol Hepatol 1995; 7: 1025-1030.
8. Feagan BG and Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database ofSystematic Reviews 2012; 10.
9. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (The IBSEN Study). Inflamm Bowel Dis 2006; 12: 543-550.
10. Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: Patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102: 1692-1701.
11. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil-dominating protein calprotectin in feces. A méthodologie study. Scand J Gastroenterol 1992; 27: 793-798.
12. Tibbie JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460.
13. Sipponen T, Savilahti E, Kolho KL, et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn’s disease activity index and endo-scopic findings. Inflamm Bowel Dis 2008; 14: 40-46.
14. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: Correlation of the Rachmilewitz endo-scopic activity index with fecal calprotectin, clinical activity, C-reactive protein and blood leukocytes. Inflamm BowelDis 2009; 15: 1851-1858.
15. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
16. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012; 18: 1894-1899.
17. Yamamoto T, Shiraki M, Bamba T, et al. Fecal calpro-tectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2013; 29: 485-191.
18. Roseth AG, Aadland E and Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39: 1017-1020.
19. Wagner M, Peterson CGB, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14: 5584-5589.
20. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-483.
21. Hjortswang H, Järnerot G, Curman B, et al. The Short Health Scale: A valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 2006; 41: 1196-1203.
22. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-1943.
23. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005; 54: 364-368.
24. Osterman MT, Aberra FN, Cross R, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2014; 12: 1887-1893.
25. D’Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008; 103: 2007-2014.
26. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14: 1229-1235.
27. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotec-tin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 669-673.
28. Maiden L, Takeuchi K, Baur R, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008; 14: 1413-1418.
29. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013; 19: 2111-2117.
30. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010; 4: 144-152.
31. Saini SD, Waljee AK and Higgins PDR. Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 1143-1151.
32. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97: 389-396.
33. Jonefjall B, Strid H, Ohman L, et al. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motility 2013; 25: e756-e758.